WAVE Life Sciences (NASDAQ:WVE – Get Free Report) and Oncocyte (NASDAQ:IMDX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.
Risk and Volatility
WAVE Life Sciences has a beta of -1.3, indicating that its share price is 230% less volatile than the S&P 500. Comparatively, Oncocyte has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
Valuation & Earnings
This table compares WAVE Life Sciences and Oncocyte”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| WAVE Life Sciences | $42.73 million | 21.54 | -$204.38 million | ($1.09) | -4.28 |
| Oncocyte | $4.05 million | 32.15 | -$50.22 million | ($1.49) | -2.67 |
Oncocyte has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares WAVE Life Sciences and Oncocyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| WAVE Life Sciences | -309.73% | -50.36% | -40.06% |
| Oncocyte | -2,955.63% | N/A | -107.52% |
Insider & Institutional Ownership
89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 55.3% of Oncocyte shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 2.2% of Oncocyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for WAVE Life Sciences and Oncocyte, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| WAVE Life Sciences | 1 | 1 | 14 | 0 | 2.81 |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
WAVE Life Sciences presently has a consensus price target of $22.31, suggesting a potential upside of 377.78%. Oncocyte has a consensus price target of $10.50, suggesting a potential upside of 163.82%. Given WAVE Life Sciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe WAVE Life Sciences is more favorable than Oncocyte.
Summary
WAVE Life Sciences beats Oncocyte on 9 of the 14 factors compared between the two stocks.
About WAVE Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
